JIBTVA  Vol.3 No.2 , April 2014
Induction of Tolerance to Non Steroidal Anti Inflammatory Drugs Might Be an Alternative Therapeutic in the Painful Crisis of Sickle Cell Disease
Abstract: Background and Aims: In Ivoirian’s school, the management of vaso-occlusive painful crisis in sickle cell disease requires non steroidal anti inflammatory drugs (NSAIDs). Although their effectiveness, these drugs may be accompanied by intolerance reactions. When these occur, no codified alternative therapeutic seems to be used to our knowledge. Authors aimed to evaluate the induction of tolerance to NSAIDs as an effective alternative therapeutic. Methods: 22 patients (15 men and 7 women aged from 12 to 39 years with mean age: 22.41 ± 7.88) suffering from vaso-occlusive painful crisis were enrolled. They were known to have a history of sickle cell disease and at least one episode of adverse reactions following the Ibuprofen or Diclofenac intake. A rapid protocol of oral challenge was used in patients to induce tolerance to NSAIDs. The first day, initial doses (8.82 mg for Ibuprofen and 2.20 mg for Diclofenac) were given and gradually increased at intervals of 1 hour over a total period of 6 hours. On the second and third days, the therapeutic dose has been orally administrated with an interval of 6 hours over a period of 12 hours. Results: Despite of some cases of failure that might be related to the severity of symptoms or possible patho-physiological mechanism, more than 80% of patients have successfully tolerated Diclofenac and Ibuprofen. Conclusion: This experience appears to be the first in our context. It might be used as a solution in the lack of alternative therapeutic in the management of vaso-occlusive painful crisis of sickle cell disease as well as in other diseases such as HIV infection where patients often develop intolerance to none alternative antibiotics.
Cite this paper: Romuald, D. , Amah, K. , Paul, A. , Richard, Y. , Koffi, N. and François, S. (2014) Induction of Tolerance to Non Steroidal Anti Inflammatory Drugs Might Be an Alternative Therapeutic in the Painful Crisis of Sickle Cell Disease. Journal of Immune Based Therapies, Vaccines and Antimicrobials, 3, 11-21. doi: 10.4236/jibtva.2014.32002.

[1]   La drépanocytose, C.R. (1973) Medicorama. 27-30.

[2]   Cabanne, R., Sangaré, A., et al. (1987) La prise en charge du drépanocytaire: l’expérience Ivoirienne. Annual University Abidjan série médi. 149-197.

[3]   American College of Rheumatology Ad Hoc Committee on Clinical Guidelines (1996) Guidelines for the Management of Rheumatoid Arthritis. Arthritis & Rheumatology, 39, 713-722.

[4]   Christie, P.E., Smith, C., Arm, J.P. and Lee, T.H. (1992) Aspirin Sensitive Asthma. Clinical & Experimental Allergy, 22, 171-175.

[5]   Slepian, I.K., Mathews, K.P. and McLean, J.A. (1985) Aspirin-Sensitive Asthma. Chest, 87, 386-391.

[6]   Yates, A.B. and de Shazo, R.D. (2003) Allergic and Non-Allergic Drug Reactions. South Medical Journal, 96, 1080- 1087.

[7]   Naldi, L., Conforti, A., Venegoni, M., Troncon, M.G., Caputi, A., Ghiotto, E., et al. (1999) Cutaneous Reactions to Drugs. An Analysis of Spontaneous Reports in Four Italian Regions. British Journal of Clinical Pharmacology, 48, 839-846.

[8]   Namazy, J.A. and Simon, R.A. (2002) Sensitivity to Nonsteroidal Anti-Inflammatory Drugs. Annals of Allergy, Asthma & Immunology, 89, 542-550.

[9]   Settipane, G.A. (1988) Aspirin Sensitivity and Allergy. Biomed Pharmacotherapy, 42, 493-498.

[10]   Hoigne, R., Schlumberger, H.P., Vervloet, D. and Zoppi, M. (1993) Epidemiology of Allergic Drug Reactions. Monographs in Allergy, 31, 147-170.

[11]   Sánchez-Borges, M. (2008) Clinical Management of Non-Steroidal Anti-Inflammatory Drug Hypersensitivity. WAO Journal, 1, 29-33.

[12]   Jenneck, C., Juergens, U., Buecheler, M. and Novak, N. (2007) Pathogenesis, Diagnosis, and Treatment of Aspirin Intolerance. Annals of Allergy, Asthma & Immunology, 99, 13-21.

[13]   Romuald, D.S., Koffi, N., Paul, A.D., Rita, Y. and Francois, S.M. (2011) Manifestations respiratoires induites par les anti-inflammatoires non stéroidiens chez le drépanocytaire. Sante, 21, 187-191.

[14]   Johansson, S.G.O., O’B Hourihane, J., Bousquet, J., Bruijnzeel-Koomen, C., Dreborg, S., Haahtela, T., Kowalski, M.L., Mygind, N., Ring, J., van Cauwenberge, P., van Hage-Hamsten, M. and Wüthrich, B. (2001) A Revised Nomenclature for Allergy: An EAACI Position Statement from the EAACI Nomenclature Task Force. Allergy, 56, 813-824.

[15]   Abuaf, N., Rostane, H., Barbara, J., Toly-Ndour, C., Gaouar, H., Mathelier-Fusade, P., Leynadier, F., Francès, C. and Girot, R. (2012) Comparison of CD63 Upregulation Induced by NSAIDs on Basophils and Monocytes in Patients with NSAID. Journal of Allergy (Cairo), 2012, 580873.

[16]   Kowalski, M.L., Makowska, J.S., Blanca, M., Bavbek, S., Bochenek, G., Bousquet, J., Bousquet, P., Celik, G., Demoly, P., Gomes, E.R., Nizankowska-Mogilnicka, E., Romano, A., Sanchez-Borges, M., Sanz, M., Torres, M.J., De Weck, A., Szczeklik, A. and Brockow, K. (2011) Hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)-Classification, Diagnosis and Management: Review of the EAACI/ENDA and GA2LEN/HANNA. Allergy, 66, 818-829.

[17]   Kasper, L., Sladek, K., Duplaga, M., et al. (2003) Prevalence of Asthma with Aspirin Hypersensitivity in the Adult Population of Poland. Allergy, 58, 1064-1066.

[18]   Juhlin, L. (1981) Recurrent Urticaria: Clinical Investigation of 330 Patients. British Journal of Dermatology, 104, 369-381.

[19]   Setkowicz, M., Mastalerz, L., Podolec-Rubis, M., Sanak, M. and Szczeklik, A. (2009) Clinical Course and Urinary Eicosanoids in Patients with Aspirin-Induced Urticaria Followed up for 4 Years. Journal of Allergy and Clinical Immunology, 123, 174-178.

[20]   Szczeklik, A., Nizankowska-Mogilnicka, E. and Sanak, M. (2009) Hypersensitivity to Aspirin and Nonsteroidal Anti-Inflammatory Drugs. In: Adkinson Jr., N.F., Bochner, B.S., Busse, W.W., Holgate, S.T., Lemanske Jr., R.F. and Simons, F.E.R., Eds., Middleton’s Allergy: Principles and Practice, 7th Edition, Mosby Elsevier, New York, 1227-1243.

[21]   Stevenson, D.D., Sanchez-Borges, M. and Szczeklik, A. (2001) Classification of Allergic and Pseudoallergic Reactions to Drugs that Inhibit Cyclooxygenase Enzymes. Annals of Allergy, Asthma & Immunology, 87, 177-180.

[22]   Makowska, J.S., Grzegorczyk, J., Bienkiewicz, B., Wozniak, M. and Kowalski, M.L. (2008) Systemic Responses after Bronchial Aspirin Challenge in Sensitive Patients with Asthma. Journal of Allergy and Clinical Immunology, 121, 348-354.

[23]   Pérez-Calderón, R., Gonzalo-Garijo, M.A., Pérez-Rangel, I., Sánchez-Vega, S. and Zambonino, M.A. (2011) Fixed Drug Eruption Due to Nabumetone in a Patient with Previous Fixed Drug Eruptions Due to Naproxen. Journal of Investigational Allergology and Clinical Immunology, 21, 153-154.

[24]   Kim, H.A., Ye, Y.M., Kim, S.H., Hur, G.Y. and Park, H.S. (2007) Association of β2-Adrenergic Receptor Polymorphism with the Phenotype of Aspirin-Intolerant Acute Urticaria. Yonsei Medical Journal, 48, 1079-1081.

[25]   Kim, Shin-Hyun, Choi, J.H., Lee, K.W., Kim, Se-Heon, Shin, E.S., Oh, H.B., Suh, C.H., Nahm, D.H. and Park, H.S. (2005) The Human Leucocyte Antigen-DRB1*1302-DQB1*0609-DPB1*0201 Haplotype May be a Strong Genetic Marker for Aspirin-Induced Urticaria. Clinical and Experimental Allergy, 35, 339-344.

[26]   Stevenson, D.D. and Simon, R.A. (2001) Lack of Cross-Reactivity between Rofecoxib and Aspirin in Aspirin-Sensitive Patients with Asthma. Journal of Allergy and Clinical Immunology, 108, 47-51.

[27]   Zembowicz, A., Mastalerz, L., Setkowicz, M., Radziszewski, W. and Szczeklik, A. (2003) Safety of Cyclooxygenase 2 Inhibitors and Increased Leukotriene Synthesis in Chronic Idiopathic Urticaria with Sensitivity to Nonsteroidal Anti- Inflammatory Drugs. JAMA Dermatology, 139, 1577-1582.

[28]   Gómez, E., Jose Torres, M., Mayorga, C. and Blanca, M. (2012) Immunologic Evaluation of Drug Allergy. Allergy, Asthma & Immunology Research, 4, 251-263.

[29]   Quiralte, J., Blanco, C., Delgado, J., Ortega, N., Alcntára, M., Castillo, R., Anguita, J.L., Sáenz de San Pedro, B. and Carrillo, T. (2007) Challenge-Based Clinical Patterns of 223 Spanish Patients with Nonsteroidal Anti-Inflammatory-Drug-Induced-Reactions. Journal of Investigational Allergology & Clinical Immunology, 17, 182-188.

[30]   Dahlen, B., Szczeklik, A. and Murray, J.J. (2001) Celecoxib in Patients with Asthma and Aspirin Intolerance. New England Journal of Medicine, 344, 142.

[31]   Sanchez-Borges, M., Caballero-Fonseca, F. and Capriles-Hulett, A. (2005) Safety of Etoricoxib, a New Cyclooxyge-nase 2 Inhibitor, in Patients with Nonsteroidal Anti-Inflammatory Drug-Induced Urticaria and Angioedema. Annals of Allergy, Asthma & Immunology, 95, 154-158.

[32]   Weberschock, T.B., Muller, S.M., Boehncke, S. and Boehncke, W.H. (2007) Tolerance to Coxibs in Patients with Intolerance to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): A Systematic Structured Review of Literature. Archives of Dermatological Research, 299, 169-175.

[33]   Cimbollek, S., Quiralte, J. and Avila, R. (2009) COX-2 Inhibitors in Patients with Sensitivity to Nonselective NSAIDs. New England Journal of Medicine, 361, 2197-2198.

[34]   Christou, A., Kafkas, N., Marinakos, A., Katsanos, S., Papanikitas, K. and Patsilinakos, S. (2011) Rapid Desensitisation of Patients with Aspirin Allergy Who Undergo Coronary Angioplasty. Hellenic Journal of Cardiology, 52, 307-310.

[35]   Messaad, D., Sahla, H., Benahmed, S., Godard, P., Bousquet, J. and Demoly, P. (2004) Drug Provocation Tests in Patients with a History Suggesting an Immediate Drug Hypersensitivity Reaction. Annals of Internal Medicine, 140, 1001-1006.

[36]   Kowalski, M.L., Makowska, J.S., Blanca, M., et al. (2011) Hypersensitivity to Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)—Classification, Diagnosis and Management: Review of the EAACI/ENDA and GA2LEN/HANNA. Allergy, 66, 818-829.

[37]   Thong, B.Y. (2011) Clinical Applications of Drug Desensitization in the Asia-Pacific Region. Asia Pacific Allergy, 1, 2-11.

[38]   Cardona, R., Ramírez, R.H., Reina, Z., Escobar, M.F. and Morales, E. (2009) Alergia e intolerancia a antiinflamatorios no esteroides: Desensibilización exitosa en tres casos y revisión de la literatura. Biomédica, 29, 181-190.

[39]   Woo, H.Y., Kim, Y.S., Kang, N.I., Chung, W.C., Song, C.H., Choi, I.W., Choi, I.H. and Lee, H.K. (2006) Mechanism for Acute Oral Desensitization to Antibiotics. Allergy, 61, 954-958.

[40]   Odom, S., Gomez, G., Kovarova, M., Furumoto, Y., Ryan, J.J., Wright, H.V., Gonzalez-Espinosa, C., Hibbs, M.L., Harder, K.W. and Rivera, J. (2004) Negative Regulation of Immunoglobulin E-Dependent Allergic Responses by Lyn kinase. Journal of Experimental Medicine, 199, 1491-1502.

[41]   Malaviya, R. and Uckun, F.M. (2002) Role of STAT6 in IgE Receptor/FcepsilonRI-Mediated Late Phase Allergic Responses of Mast Cells. Journal of Immunology, 168, 421-426.

[42]   Morales, A.R., Shah, N. and Castells, M. (2005) Antigen-IgE Desensitization in Signal Transducer and Activator of Transcription 6-Deficient Mast Cells by Suboptimal Doses of Antigen. Annals of Allergy, Asthma & Immunology, 94, 575-580.

[43]   Strobel, S. and Mowat, A.M. (2006) Oral Tolerance and Allergic Responses to Food Proteins. Current Opinion in Allergy & Clinical Immunology, 6, 207-213.

[44]   Mucida, D., Kutchukhidze, N., Erazo, A., Russo, M., Lafaille, J.J. and Curotto de Lafaille, M.A. (2005) Oral Tolerance in the Absence of Naturally Occurring Tregs. Journal of Clinical Investigation, 115, 1923-1933.

[45]   van Wijk, F., Wehrens, E.J.M., Nierkens, S., Boon, L., Kasran, A., Pieters, R. and Knippels, L.M.J. (2007) CD4+CD25+ T Cells Regulate the Intensity of Hypersensitivity Responses to Peanut but Are Not Decisive in the Induction of Oral Sensitization. Clinical & Experimental Allergy, 37, 572-581.

[46]   Martorell Aragones, A., Felix Toledo, R., Cerda Mir, J.C. and Martorell Calatayud, A. (2007) Oral Rush Desensitization to Cow Milk. Following of Desensitized Patients during Three Years. Allergologia et Immunopathologia, 35, 174-176.

[47]   Staden, U., Blumchen, K., Blankenstein, N., Dannenberg, N., Ulbricht, H., Dobberstein, K., Ziegert, M., Niggemann, B., Wahn, U. and Beyer, K. (2008) Rush Oral Immunotherapy in Children with Persistent Cow’s Milk Allergy. Journal of Allergy and Clinical Immunology, 122, 418-419.

[48]   Meglio, P., Bartone, E., Plantamura, M., Arabito, E. and Giampietro, P.G. (2004) A Protocol for Oral Desensitization in Children with IgE-Mediated Cow’s Milk Allergy. Allergy, 59, 980-987.

[49]   Szczeklik, A. and Stevenson, D.D. (1999) Aspirin-Induced Asthma: Advances in Pathogenesis and Management. Journal of Allergy and Clinical Immunology, 104, 5-13.

[50]   Rossini, R., Angiolillo, D.J., Musumeci, G., Scuri, P., Invernizzi, P., Bass, T.A., Mihalcsik, L. and Gavazzi, A. (2008) Aspirin Desensitization in Patients Undergoing Percutaneous Coronary Interventions with Stent Implantation. American Journal of Cardiology, 101, 786-789.

[51]   Warrington, R. and Silviu-Dan, F. (2011) Drug Allergy. Allergy, Asthma & Clinical Immunology, 7, S10.